The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials

Table 1

Characteristics of the studies included in the meta-analysis.

Study	Clinical trials	Phase	Patients	Immune target	Experimental arms	Control arms	Therapeutic line	Primary outcome
Rittmeyer et al. (2016)	OAK	III	850	PD-L1	Atezolizumab	Docetaxel	>1	OS
Borghaei et al. (2015)	CHECKMATE 057	III	582	PD-1	Nivolumab	Docetaxel	>1	OS
Fehrenbacher et al. (2016)	POPLAR	II	287	PD-L1	Atezolizumab	Docetaxel	>1	OS
Socinski et al. (2018)	IMPOWER150	III	692	PD-L1	Atezolizumab+BCP	BCP	1	PFS
Arrieta et al. (2020)	PROLUNG	II	78	PD-1	Pembrolizumab+docetaxel	Docetaxel	1	PFS
Patel et al. (2020)	PACIFIC	III	713	PD-1	Pembrolizumab+docetaxel	Docetaxel	1	PFS
Herbst et al. (2019)	KEYNOTE-042	II	782	PD-1	Pembrolizumab	Docetaxel	1	OS, PFS
Herbst et al. (2016)	KEYNOTE-010	II/III	1033	PD-1	Nivolumab	Docetaxel		OS
Gadgeel et al. (2019)	KEYNOTE-189	II	616	PD-1	Pembrolizumab+docetaxel	Docetaxel	1	OS, PFS

BCP: bevacizumab plus carboplatin plus paclitaxel.